We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+34.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.26B
AUM Growth
+$251M
Cap. Flow
-$193M
Cap. Flow %
-4.53%
Top 10 Hldgs %
40.49%
Holding
127
New
24
Increased
16
Reduced
24
Closed
18

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$52.4M
2
CI icon
Cigna
CI
+$48.2M
3
UTHR icon
United Therapeutics
UTHR
+$38.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$29.4M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$28.9M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$105M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$93.6M
3
THC icon
Tenet Healthcare
THC
+$81.8M
4
BSX icon
Boston Scientific
BSX
+$39.8M
5
CYTK icon
Cytokinetics
CYTK
+$35.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRVS icon
26
Corvus Pharmaceuticals
CRVS
$1.19B
$52.8M 1.24%
7,165,006
– –
APLS
27
DELISTED
Apellis Pharmaceuticals
APLS
$52.6M 1.24%
2,323,368
+841,068
+57% +$19.6M
DHR icon
28
Danaher
DHR
$152B
$52.2M 1.23%
+263,100
New +$52.4M
NBIX icon
29
Neurocrine Biosciences
NBIX
$15.7B
$49.6M 1.17%
353,640
-84,900
-19% -$11.5M
UTHR icon
30
United Therapeutics
UTHR
$22.1B
$48.2M 1.13%
+114,900
New +$38.6M
CI icon
31
Cigna
CI
$73.7B
$46.9M 1.1%
+162,800
New +$48.2M
CRNX icon
32
Crinetics Pharmaceuticals
CRNX
$9B
$45.8M 1.08%
1,099,000
-50,000
-4% -$1.6M
ORIC icon
33
Oric Pharmaceuticals
ORIC
$1.37B
$43.7M 1.03%
3,641,756
+2,742,475
+305% +$28.9M
JANX icon
34
Janux Therapeutics
JANX
$1.1B
$43.2M 1.01%
1,766,100
+555,800
+46% +$13.5M
ROIV icon
35
Roivant Sciences
ROIV
$25.1B
$41.1M 0.97%
2,714,798
-64,629
-2% -$800K
ASND icon
36
Ascendis Pharma A/S
ASND
$16.3B
$38.2M 0.9%
191,905
+157,505
+458% +$29.4M
SIBN icon
37
SI-BONE Inc
SIBN
$861M
$38M 0.89%
2,578,979
– –
SCPH
38
DELISTED
scPharmaceuticals
SCPH
$34.4M 0.81%
6,059,528
– –
ABVX
39
Abivax
ABVX
$9.89B
$32.3M 0.76%
+380,000
New +$23.3M
GPCR icon
40
Structure Therapeutics
GPCR
$3.38B
$31.9M 0.75%
1,139,300
-60,000
-5% -$1.2M
TRVI icon
41
Trevi Therapeutics
TRVI
$2.39B
$30.3M 0.71%
3,308,400
– –
ITGR icon
42
Integer Holdings
ITGR
$4.26B
$30M 0.7%
290,000
-143,400
-33% -$15.6M
DYN icon
43
Dyne Therapeutics
DYN
$4.68B
$29.3M 0.69%
2,314,184
+1,282,784
+124% +$14.6M
RAPT
44
DELISTED
RAPT Therapeutics
RAPT
$28M 0.66%
1,086,618
-555,288
-34% -$7.27M
CTMX icon
45
CytomX Therapeutics
CTMX
$699M
$27M 0.63%
8,461,500
– –
NPCE icon
46
Neuropace
NPCE
$495M
$27M 0.63%
2,614,184
– –
QURE icon
47
uniQure
QURE
$3.38B
$26.8M 0.63%
+458,500
New +$8.32M
EYPT icon
48
EyePoint Inc
EYPT
$386M
$25.6M 0.6%
+1,796,000
New +$20.7M
AKRO
49
DELISTED
Akero Therapeutics
AKRO
$25M 0.59%
526,200
+314,900
+149% +$15.2M
ADCT icon
50
ADC Therapeutics
ADCT
$146M
$23.6M 0.56%
5,907,351
– –
1
2
3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2025 Portfolio in Review

As of Q3 2025, OrbiMed held 127 positions worth $4.26B, up 6.3% from $4B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $193M in Q3 2025, closing 18 positions and reducing 24 holdings. Its most notable exit was UnitedHealth, an estimated $105M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Danaher worth $52.2M.

  • OrbiMed's largest Q3 2025 buy was Danaher: 263,100 shares worth $52.2M.
  • OrbiMed added most to Ascendis Pharma A/S in Q3 2025, an estimated $29.4M increase.
  • OrbiMed's biggest Q3 2025 reduction was Boston Scientific, cutting an estimated $39.8M.
  • OrbiMed fully exited UnitedHealth in Q3 2025, selling an estimated $105M.
  • OrbiMed's ten largest holdings make up 40% of its $4.26B portfolio in Q3 2025.
  • OrbiMed opened 24 new positions and closed 18 in Q3 2025.
  • OrbiMed's portfolio value rose 6.3% quarter-over-quarter to $4.26B.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.